[1] |
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II) [J]. J Vasc Surg, 2007, 45(Suppl S): S5-67.
|
[2] |
Singh GD, Armstrong EJ, Laird JR. Femoropopliteal in-stent restenosis: current treatment strategies [J]. J Cardiovasc Surg (Torino), 2014, 55(3): 325-333
|
[3] |
Baril DT, Rhee RY, Kim J, et al. Duplex criteria for determination of in-stent stenosis after angioplasty and stenting of the superficial femoral artery [J]. J Vasc Surg, 2009, 49(1): 133-138.
|
[4] |
Aghel A, Armstrong EJ. Recent advances in self-expanding stents for use in the superficial femoral and popliteal arteries [J]. Expert Rev Cardiovasc Ther, 2014, 12(7): 833-842.
|
[5] |
Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Consensus (TASC) [J]. J Vasc Surg, 2000, 31(1pt 2): S1-S296.
|
[6] |
Krankenberg H, Tübler T, Sixt S, et al. German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization [J]. J Endovasc Ther, 2014, 21(4): 463-471.
|
[7] |
Sultan S, Tawfick W, Hynes N. Ten-year technical and clinical outcomes in TransAtlantic Inter-Society Consensus II infrainguinal C/D lesionss using duplex ultrasound arterial mapping as the sole imaging modality for critical lower limb ischemia [J]. J Vasc Surg, 2013, 57(4): 1038-1045
|
[8] |
Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study [J]. J Endovasc Ther, 2009, 16(3): 261-269.
|
[9] |
Matsumura JS, Yamanouchi D, Goldstein JA, et al. The united states study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the protégé everflex nitinol stent system II (DURABILITY II) [J]. J Vasc Surg, 2013, 58(1): 73-83.
|
[10] |
Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting [J]. Circulation, 2007, 115(21): 2745-2749.
|
[11] |
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II) [J]. Eur J Vasc Endovasc Surg, 2007, 33(Suppl 1): S1-S75.
|
[12] |
Yahagi K, Otsuka F, SakakuraK,et al. Pathophysiology of superficial femoral artery in-stent restenosis [J]. J Cardiovasc Surg (Torino), 2014, 55(3): 307-323.
|
[13] |
Iida O, Takahara M, Soga Yet al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery [J]. JACC Cardiovasc Interv, 2014, 7(7): 792-798.
|
[14] |
马天宇, 谷涌泉, 郭连瑞, 等. 糖尿病对股腘动脉支架患者预后影响的临床研究 [J]. 中华普通外科杂志, 2014, 29(8): 593-596.
|
[15] |
Galied SR, Muradin MD, Johanna L, et al. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis [J]. Radiology, 2001, 221(1): 137-145.
|